<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK91457" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK91457/" /><meta name="ncbi_pagename" content="Bietti Crystalline Dystrophy - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Bietti Crystalline Dystrophy - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Bietti Crystalline Dystrophy" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/02/07" /><meta name="citation_author" content="Mauricio Vargas" /><meta name="citation_author" content="Amanda Mitchell" /><meta name="citation_author" content="Paul Yang" /><meta name="citation_author" content="Richard Weleber" /><meta name="citation_pmid" content="22497028" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK91457/" /><meta name="citation_keywords" content="Bietti Crystalline Corneoretinal Dystrophy" /><meta name="citation_keywords" content="Bietti Crystalline Retinopathy" /><meta name="citation_keywords" content="Bietti Crystalline Retinopathy" /><meta name="citation_keywords" content="Bietti Crystalline Corneoretinal Dystrophy" /><meta name="citation_keywords" content="Cytochrome P450 4V2" /><meta name="citation_keywords" content="CYP4V2" /><meta name="citation_keywords" content="Bietti Crystalline Dystrophy" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Bietti Crystalline Dystrophy" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Mauricio Vargas" /><meta name="DC.Contributor" content="Amanda Mitchell" /><meta name="DC.Contributor" content="Paul Yang" /><meta name="DC.Contributor" content="Richard Weleber" /><meta name="DC.Date" content="2019/02/07" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK91457/" /><meta name="description" content="Bietti crystalline dystrophy (BCD) is a chorioretinal degeneration characterized by the presence of yellow-white crystals and/or complex lipid deposits in the retina and (to a variable degree) the cornea. Progressive atrophy and degeneration of the retinal pigment epithelium (RPE) / choroid lead to symptoms similar to those of other forms of retinal degeneration that fall under the category of retinitis pigmentosa and allied disorders, namely: reduced visual acuity, poor night vision, abnormal retinal electrophysiology, visual field loss, and often impaired color vision. Marked asymmetry between eyes is not uncommon. Onset is typically during the second to third decade of life, but ranges from the early teenage years to beyond the third decade. With time, loss of peripheral visual field, central acuity, or both result in legal blindness in most if not all affected individuals." /><meta name="og:title" content="Bietti Crystalline Dystrophy" /><meta name="og:type" content="book" /><meta name="og:description" content="Bietti crystalline dystrophy (BCD) is a chorioretinal degeneration characterized by the presence of yellow-white crystals and/or complex lipid deposits in the retina and (to a variable degree) the cornea. Progressive atrophy and degeneration of the retinal pigment epithelium (RPE) / choroid lead to symptoms similar to those of other forms of retinal degeneration that fall under the category of retinitis pigmentosa and allied disorders, namely: reduced visual acuity, poor night vision, abnormal retinal electrophysiology, visual field loss, and often impaired color vision. Marked asymmetry between eyes is not uncommon. Onset is typically during the second to third decade of life, but ranges from the early teenage years to beyond the third decade. With time, loss of peripheral visual field, central acuity, or both result in legal blindness in most if not all affected individuals." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK91457/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/bietti-cd/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK91457/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE886066DFC85D7100000000074C0345.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK91457_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK91457_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/b-thal/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bgd-biotin/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK91457_"><span class="title" itemprop="name">Bietti Crystalline Dystrophy</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Retinopathy</div><p class="contrib-group"><span itemprop="author">Mauricio Vargas</span>, MD, PhD, <span itemprop="author">Amanda Mitchell</span>, MS, CGC, <span itemprop="author">Paul Yang</span>, MD, PhD, and <span itemprop="author">Richard Weleber</span>, MD, DABMG, FACMG.</p><a data-jig="ncbitoggler" href="#__NBK91457_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK91457_ai__"><div class="contrib half_rhythm"><span itemprop="author">Mauricio Vargas</span>, MD, PhD<div class="affiliation small">Ophthalmic Genetics Service<br />Casey Eye Institute<br />Oregon Health Sciences University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@amsagrav" class="oemail">ude.usho@amsagrav</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Amanda Mitchell</span>, MS, CGC<div class="affiliation small">Genetic Counselor, Casey Eye Institute<br />Oregon Health Sciences University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@maehctim" class="oemail">ude.usho@maehctim</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Paul Yang</span>, MD, PhD<div class="affiliation small">Casey Eye Institute<br />Oregon Health Sciences University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@pgnay" class="oemail">ude.usho@pgnay</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Richard Weleber</span>, MD, DABMG, FACMG<div class="affiliation small">Ophthalmic Genetics Service<br />Casey Eye Institute<br />Oregon Health Sciences University<br />Portland, Oregon<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.usho@rrebelew" class="oemail">ude.usho@rrebelew</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">April 12, 2012</span>; Last Update: <span itemprop="dateModified">February 7, 2019</span>.</p><p><em>Estimated reading time: 22 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="bietti-cd.Summary" itemprop="description"><h2 id="_bietti-cd_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Bietti crystalline dystrophy (BCD) is a chorioretinal degeneration characterized by the presence of yellow-white crystals and/or complex lipid deposits in the retina and (to a variable degree) the cornea. Progressive atrophy and degeneration of the retinal pigment epithelium (RPE) / choroid lead to symptoms similar to those of other forms of retinal degeneration that fall under the category of retinitis pigmentosa and allied disorders, namely: reduced visual acuity, poor night vision, abnormal retinal electrophysiology, visual field loss, and often impaired color vision. Marked asymmetry between eyes is not uncommon. Onset is typically during the second to third decade of life, but ranges from the early teenage years to beyond the third decade. With time, loss of peripheral visual field, central acuity, or both result in legal blindness in most if not all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of BCD is based on the finding of numerous small, glistening yellow-white retinal crystals associated with atrophy of the RPE, pigment clumps, and sclerosis of the choroidal vessels; variable crystalline deposits in the corneal limbus; varying degrees of rod and cone dysfunction on electroretinography; visual field defects; and reflective dots visualized by spectral <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> optical coherence tomography. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CYP4V2</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can confirm the diagnosis if clinical features are inconclusive.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Referral to low-vision specialists and organizations/professionals trained to work with the visually impaired.</p><p><i>Surveillance:</i> Periodic ophthalmologic examination to monitor disease progression and periodic visual field testing particularly as it relates to determination of driving eligibility and eligibility for government programs and/or disability.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>BCD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.</p></div></div><div id="bietti-cd.Diagnosis"><h2 id="_bietti-cd_Diagnosis_">Diagnosis</h2><p>The diagnosis of BCD, a chorioretinal degeneration, is based on the clinical findings of the typical crystalline deposits in the cornea and retina. BCD is one of few ocular diseases for which the diagnosis can be made with a high degree of confidence by careful examination alone.</p><div id="bietti-cd.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Bietti crystalline dystrophy <b>should be suspected</b> in individuals with the following clinical, electrophysiology, and optical coherence tomography (OCT) findings.</p><div id="bietti-cd.Clinical_Findings"><h4>Clinical Findings</h4><p><b>Vision impairment.</b> Onset of impairment is typically during the second or third decade of life; however, age of onset, presenting symptoms, and disease severity vary widely. Vison impairment is progressive. Marked asymmetry between eyes is common.</p><ul><li class="half_rhythm"><div>Visual field loss. Visual field defects are variable and correlate with atrophic lesions that can encroach on the central vision.</div></li><li class="half_rhythm"><div>Nyctalopia (i.e., night blindness)</div></li><li class="half_rhythm"><div>Reduction in visual acuity</div></li></ul><p><b>Retina</b></p><ul><li class="half_rhythm"><div>Numerous small, glistening yellow-white crystals scattered throughout the posterior pole may extend to the midperiphery; crystalline deposits may tend to diminish with advanced disease.</div></li><li class="half_rhythm"><div>Atrophy of the retinal pigment epithelium (RPE) and choriocapillaris</div></li><li class="half_rhythm"><div>Pigment clumping</div></li><li class="half_rhythm"><div>Sclerosis of the choroidal vessels</div></li><li class="half_rhythm"><div>Patchy hypofluorescent areas of RPE, choriocapillaris atrophy, and a generalized disturbance of the RPE seen on fluorescein angiography</div></li></ul><p><b>Cornea.</b> Crystalline deposits in the corneal limbus (~25%-33%) are usually seen on slit lamp examination but are not necessary for diagnosis.</p><p>Spectral microscopy may be appropriate if corneal crystalline deposits are too subtle to detect on slit lamp examination.</p></div><div id="bietti-cd.Electrophysiology"><h4>Electrophysiology</h4><p><b>Full-field electroretinogram (ffERG)</b> can show varying degrees of rod and cone dysfunction, ranging from normal to reduced amplitudes of scotopic and photopic responses to undetectable responses [<a class="bk_pop" href="#bietti-cd.REF.usui.2001.395">Usui et al 2001</a>]. Note: The ffERG can remain normal even in later stages of the disease.</p><p><b>Multifocal electroretinogram (mfERG)</b> may detect regional areas of abnormal retinal function when the ffERG is normal, particularly in those regional phenotypes that predominantly affect the posterior pole.</p></div><div id="bietti-cd.Optical_Coherence_Tomography_O"><h4>Optical Coherence Tomography (OCT)</h4><p>Crystalline deposits can be seen as hyper-reflective dots in the choriocapillaris on spectral <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> OCT.</p><p>Other reflective spots of various shapes (called retinal tubulation by <a class="bk_pop" href="#bietti-cd.REF.zweifel.2009.1596">Zweifel et al [2009]</a>) can be seen by OCT. <a class="bk_pop" href="#bietti-cd.REF.kojima.2012.390">Kojima et al [2012]</a> reported the presence of spherical, hyper-refractive structures in the outer nuclear layer of the retina, in areas of RPE atrophy.</p><p>The degeneration in BCD seen by OCT is most prominent in the outer retina, including the photoreceptor layer, but the degeneration is not uniformly distributed.</p></div></div><div id="bietti-cd.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of Bietti crystalline dystrophy <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with the above <a href="#bietti-cd.Suggestive_Findings">Suggestive Findings</a>. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>CYP4V2</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK91457/table/bietti-cd.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="figbietticdTmoleculargenetictestingus" rid-ob="figobbietticdTmoleculargenetictestingus">Table 1</a>) can confirm the diagnosis if clinical features are inconclusive.</p><p>Molecular genetic testing approaches can include <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing or <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>). Depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, <b>more</b>
<b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) could be considered if <i>CYP4V2</i> pathogenic variants are not found by targeted testing.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of Bietti crystalline dystrophy is broad, individuals with the distinctive findings described in <a href="#bietti-cd.Suggestive_Findings">Suggestive Findings</a> are likely to be diagnosed using gene-targeted testing (see <a href="#bietti-cd.Option_1">Option 1</a>), whereas those with a phenotype indistinguishable from many other inherited disorders with chorioretinal degeneration are more likely to be diagnosed using genomic testing (see <a href="#bietti-cd.Option_2">Option 2</a>).</p><div id="bietti-cd.Option_1"><h4>Option 1</h4><p>When the phenotypic and laboratory findings suggest the diagnosis of Bietti crystalline dystrophy, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>CYP4V2</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>CYP4V2</i> and other genes of interest (see <a href="#bietti-cd.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul></div><div id="bietti-cd.Option_2"><h4>Option 2</h4><p>When the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is indistinguishable from many other inherited disorders characterized by chorioretinal degeneration, <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) may be the best option. <b>Exome sequencing</b> is most commonly used; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible.</p><p>If <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is not diagnostic, <b><a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a></b> (when clinically available) may be considered to detect (multi)<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="bietti-cd.T.molecular_genetic_testing_us" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Bietti Crystalline Dystrophy</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK91457/table/bietti-cd.T.molecular_genetic_testing_us/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bietti-cd.T.molecular_genetic_testing_us_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bietti-cd.T.molecular_genetic_testing_us_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_bietti-cd.T.molecular_genetic_testing_us_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_bietti-cd.T.molecular_genetic_testing_us_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_bietti-cd.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>CYP4V2</i></td><td headers="hd_h_bietti-cd.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_bietti-cd.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;93% - 97.7%&#x000a0;<sup>4,&#x000a0;5,&#x000a0;6</sup></td></tr><tr><td headers="hd_h_bietti-cd.T.molecular_genetic_testing_us_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>7</sup></td><td headers="hd_h_bietti-cd.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">2 individuals&#x000a0;<sup>8,&#x000a0;9</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="bietti-cd.TF.1.1"><p class="no_margin">See <a href="/books/NBK91457/#bietti-cd.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="bietti-cd.TF.1.2"><p class="no_margin">See <a href="#bietti-cd.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="bietti-cd.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="bietti-cd.TF.1.4"><p class="no_margin">Pathogenic variants were identified in 95.4% (N=109) families or 93.6% of alleles [<a class="bk_pop" href="#bietti-cd.REF.xiao.2011.181">Xiao et al 2011</a>].</p></div></dd><dt>5. </dt><dd><div id="bietti-cd.TF.1.5"><p class="no_margin">In a study from Japan, eight probands were found to have mutation of <i>CYP4V2</i>, including seven with the <a class="figpopup" href="/books/NBK91457/table/bietti-cd.T.cyp4v2_pathogenic_variants_d/?report=objectonly" target="object" rid-figpopup="figbietticdTcyp4v2pathogenicvariantsd" rid-ob="figobbietticdTcyp4v2pathogenicvariantsd">c.802-8_810delinsGC</a> (reported as IVS6-8_c.810del/insGC) variant, suggesting a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>.</p></div></dd><dt>6. </dt><dd><div id="bietti-cd.TF.1.6"><p class="no_margin"><i>CP4V2</i> pathogenic variants have been detected in 97.7% of individuals of Chinese descent [<a class="bk_pop" href="#bietti-cd.REF.zhang.2018.700">Zhang et al 2018</a>].</p></div></dd><dt>7. </dt><dd><div id="bietti-cd.TF.1.7"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>8. </dt><dd><div id="bietti-cd.TF.1.8"><p class="no_margin">A large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> encompassing <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 8 was reported by <a class="bk_pop" href="#bietti-cd.REF.zhang.2018.700">Zhang et al [2018]</a>.</p></div></dd><dt>9. </dt><dd><div id="bietti-cd.TF.1.9"><p class="no_margin">A ~4-Mb <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> encompassing <i>CYP4V2</i> and several adjacent genes was identified in an individual with BCD from Germany [<a class="bk_pop" href="#bietti-cd.REF.astuti.2015.14">Astuti et al 2015</a>].</p></div></dd></dl></div></div></div></div></div></div><div id="bietti-cd.Clinical_Characteristics"><h2 id="_bietti-cd_Clinical_Characteristics_">Clinical Characteristics</h2><div id="bietti-cd.Clinical_Description"><h3>Clinical Description</h3><p>Bietti crystalline dystrophy (BCD) is characerized by progressive chorioretinal degeneration with onset typically during the second to third decade of life (range: early teens to &#x0003e;3<sup>rd</sup> decade). The symptoms, ranges of visual impairment, and disabilities are similar to those of individuals with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <a href="/books/n/gene/rp-overview/">retinitis pigmentosa</a>.</p><p>The presenting symptom, rate of disease progression, and disease severity are also highly variable in BCD, even among those of the same age, within the same family, and with the same <i>CYP4V2</i> pathogenic variants [<a class="bk_pop" href="#bietti-cd.REF.lee.2005.3812">Lee et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.lin.2005.e38">Lin et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.xiao.2011.181">Xiao et al 2011</a>]. Some individuals have a more diffuse retinal disease presentation, whereas others present with more localized disease in the paracentral and central regions.</p><p><b>Vision impairment.</b> In most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, onset of disease is during the second or third decade of life; however, age of onset, presenting symptoms, and disease severity vary widely. Marked asymmetry between eyes with respect to fundus appearance, reduction in visual acuity, and visual field loss is not uncommon.</p><ul><li class="half_rhythm"><div><b>Visual field loss</b> (progressive). Visual field loss may manifest in different individuals as peripheral field loss (ring, paracentral, or central scotoma) or central or pericentral scotomas (usually associated with atrophic lesions that encroach on the foveal region of the macula).</div></li><li class="half_rhythm"><div><b>Nyctalopia</b> (progressive). Night blindness (i.e., difficulty seeing in low light) is a nonspecific feature of BCD in that it is typical of many forms of inherited retinal degeneration.</div></li><li class="half_rhythm"><div><b>Reduction in visual acuity</b> (progressive). Visual acuity can range from normal to hand motion. Although the reduction in visual acuity has been reported to typically result in legal blindness by the fifth or sixth decade, central vision can sometimes be spared even in persons with severe disease. More often, loss of central visual acuity reflects atrophy or degenerative change close to or including the fovea.</div></li><li class="half_rhythm"><div>Persons with BCD may also have impaired color vision, particularly if the atrophic lesion encroaches on the fovea or cystoid macular edema is present.</div></li></ul><p>In early or milder stages of disease, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals can drive a car; with time, however, loss of peripheral visual field and/or central acuity results in legal blindness in most if not all affected individuals. Whereas affected individuals typically have profound vision loss by the fifth or sixth decade of life, central acuity can be spared through late stages of the disease in some [<a class="bk_pop" href="#bietti-cd.REF.kaiserkupfer.1994.569">Kaiser-Kupfer et al 1994</a>, <a class="bk_pop" href="#bietti-cd.REF.lee.2005.3812">Lee et al 2005</a>]. A study involving 21 families with BCD showed visual acuities ranging from normal to hand motion [<a class="bk_pop" href="#bietti-cd.REF.xiao.2011.181">Xiao et al 2011</a>].</p><p><b>Retina.</b> Numerous small, glistening yellow-white crystals are scattered throughout the posterior pole and sometimes extend to the midperiphery. The crystalline deposits are associated with atrophy of the retinal pigment epithelium (RPE) and choriocapillaris, pigment clumping, and sclerosis of the choroidal vessels.</p><p>The crystalline deposits have been observed to diminish or even disappear in areas of severe chorioretinal atrophy as the disease progresses to later stages [<a class="bk_pop" href="#bietti-cd.REF.chen.2008.237">Chen et al 2008</a>, <a class="bk_pop" href="#bietti-cd.REF.xiao.2011.181">Xiao et al 2011</a>]. Areas in which crystals are still present may represent retina that is still only mildly degenerated or in the process of degenerating [<a class="bk_pop" href="#bietti-cd.REF.kojima.2012.390">Kojima et al 2012</a>].</p><p>Fluorescein angiography reveals patchy hypofluorescent areas of RPE and choriocapillaris atrophy and a generalized disturbance of the RPE.</p><p>Additional potential retinal complications of BCD include choroidal neovascularization [<a class="bk_pop" href="#bietti-cd.REF.atmaca.2007.839">Atmaca et al 2007</a>, <a class="bk_pop" href="#bietti-cd.REF.gupta.2011.59">Gupta et al 2011</a>, <a class="bk_pop" href="#bietti-cd.REF.li.2015.2074">Li et al 2015</a>] and macular hole [<a class="bk_pop" href="#bietti-cd.REF.zhu.2009.660">Zhu et al 2009</a>].</p><p><b>Cornea.</b> Crystalline deposits in the corneal limbus have been estimated to occur in one quarter to one third of persons with BCD [<a class="bk_pop" href="#bietti-cd.REF.kaiserkupfer.1994.569">Kaiser-Kupfer et al 1994</a>, <a class="bk_pop" href="#bietti-cd.REF.halford.2014.1174">Halford et al 2014</a>]. It has also been reported that corneal deposits may be more common in persons of northern European background than in Asians [<a class="bk_pop" href="#bietti-cd.REF.traboulsi.1987.156">Traboulsi &#x00026; Faris 1987</a>].</p><p>If present, the deposits can usually be seen on slit lamp examination. However, some crystals may be so fine as to go undetected unless specifically and carefully sought; <a class="bk_pop" href="#bietti-cd.REF.takikawa.1992.969">Takikawa et al [1992]</a> suggest that in some individuals with BCD, corneal crystalline deposits may be too subtle to detect on slit lamp examination. Spectral microscopy may be more appropriate in such individuals.</p><p><b>Electrophysiology.</b> The <b>full-field electroretinogram (ffERG)</b> can show varying degrees of rod and cone dysfunction, ranging from normal to reduced amplitudes of scotopic and photopic responses to undetectable responses [<a class="bk_pop" href="#bietti-cd.REF.usui.2001.395">Usui et al 2001</a>]. The ffERG is more likely to be abnormal in mid- to late-stage disease, when the peripheral visual field is markedly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>. The multifocal electroretinogram (mfERG) is more likely to be abnormal when central function (e.g., visual acuity, central visual fields) are abnormal. Subnormal responses occur more often for the mfERG earlier in the course of disease than amplitudes of the ffERG. Thus, electrophysiologic studies are not as critical to establishing the diagnosis of BCD as they are to establishing the magnitude and extent of retinal degeneration and in following progression over time.</p><p>Although studies have shown that the ffERG responses appear to correlate well with stages of disease severity [<a class="bk_pop" href="#bietti-cd.REF.usui.2001.395">Usui et al 2001</a>, <a class="bk_pop" href="#bietti-cd.REF.lee.2005.3812">Lee et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.mansour.2007.680">Mansour et al 2007</a>], this is not always the case:</p><ul><li class="half_rhythm"><div>The ffERG can remain normal or near normal even in later stages of the disease. Normal ffERG responses can occur in individuals with BCD with severe atrophy of the RPE and choroid, suggesting that the neural retina may remain viable despite disruption of retinal lamination [<a class="bk_pop" href="#bietti-cd.REF.rossi.2011.118">Rossi et al 2011</a>].</div></li><li class="half_rhythm"><div>Regional forms of BCD that may have normal ffERGs have also been described [<a class="bk_pop" href="#bietti-cd.REF.wilson.1989.213">Wilson et al 1989</a>, <a class="bk_pop" href="#bietti-cd.REF.weleber.1991">Weleber &#x00026; Wilson 1991</a>, <a class="bk_pop" href="#bietti-cd.REF.rossi.2011.118">Rossi et al 2011</a>].</div></li></ul><p><b>A multifocal electroretinogram (mfERG)</b> may detect regional areas of abnormal retinal function when the ffERG is normal, particularly in those regional phenotypes that predominantly affect the posterior pole [<a class="bk_pop" href="#bietti-cd.REF.lockhart.2018.187">Lockhart et al 2018</a>].</p><p>This degree of variation of electrophysiology may be the result of testing at different stages of disease progression. This variability may also reflect variation in loss of function in the <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>, with alleles with residual function associated with greater retention of ffERG amplitudes.</p><p><b>Fundus autofluorescence (FAF)</b> is useful in monitoring disease extent and progression over time with regions of RPE atrophy showing relative decrease in FAF (hypo-AF). Retinal crystals have not been reported to generate an autofluorescence signal [<a class="bk_pop" href="#bietti-cd.REF.halford.2014.1174">Halford et al 2014</a>, <a class="bk_pop" href="#bietti-cd.REF.li.2015.2074">Li et al 2015</a>].</p><p><b>Optical coherence tomography (OCT).</b> Spectral <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> OCT is of value for both diagnosis and management of BCD.</p><p>Using OCT, the integrity of the outer retinal structure can be visualized in individuals with BCD, including the hyper-reflective dots thought to represent the crystalline deposits. The majority of OCT studies report that the crystalline deposits appear to reside in the RPE-choriocapillaris complex [<a class="bk_pop" href="#bietti-cd.REF.pennesi.2010.531">Pennesi &#x00026; Weleber 2010</a>, <a class="bk_pop" href="#bietti-cd.REF.padhi.2011.199">Padhi et al 2011</a>, <a class="bk_pop" href="#bietti-cd.REF.kojima.2012.390">Kojima et al 2012</a>].</p><p>In addition to the crystalline deposits, other reflective spots of various shapes (called retinal tubulation by <a class="bk_pop" href="#bietti-cd.REF.zweifel.2009.1596">Zweifel et al [2009]</a>) can be seen by OCT. <a class="bk_pop" href="#bietti-cd.REF.kojima.2012.390">Kojima et al [2012]</a> reported the presence of spherical, hyper-refractive structures in the outer nuclear layer of the retina, particularly located in areas of RPE atrophy. Of note, <a class="bk_pop" href="#bietti-cd.REF.kojima.2012.390">Kojima et al [2012]</a> also observed these same circular structures, but less frequently, in retinal dystrophies other than BCD. Drusenoid deposits can be observed at the RPE early in the disease course [<a class="bk_pop" href="#bietti-cd.REF.li.2015.2074">Li et al 2015</a>].</p><p>The degeneration in BCD seen by OCT is most prominent in the outer retina, including the photoreceptor layer, but typically the degeneration is not uniformly distributed.</p></div><div id="bietti-cd.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>A study of 125 individuals of Chinese ancestry with BCD showed that individuals who were <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for the most common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK91457/table/bietti-cd.T.cyp4v2_pathogenic_variants_d/?report=objectonly" target="object" rid-figpopup="figbietticdTcyp4v2pathogenicvariantsd" rid-ob="figobbietticdTcyp4v2pathogenicvariantsd">c.802-8_810delinsGC</a> had an earlier age of onset than those who did not have this pathogenic variant [<a class="bk_pop" href="#bietti-cd.REF.zhang.2018.700">Zhang et al 2018</a>]. Individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <a class="figpopup" href="/books/NBK91457/table/bietti-cd.T.cyp4v2_pathogenic_variants_d/?report=objectonly" target="object" rid-figpopup="figbietticdTcyp4v2pathogenicvariantsd" rid-ob="figobbietticdTcyp4v2pathogenicvariantsd">c.802-8_810delinsGC</a> also tended to have a younger age of onset than individuals with other pathogenic variants, although not to a statistically significant degree.</p><p>Another study of 18 individuals of Chinese descent with BCD showed that those who were <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for <a class="figpopup" href="/books/NBK91457/table/bietti-cd.T.cyp4v2_pathogenic_variants_d/?report=objectonly" target="object" rid-figpopup="figbietticdTcyp4v2pathogenicvariantsd" rid-ob="figobbietticdTcyp4v2pathogenicvariantsd">c.802-8_810delinsGC</a> or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> for variants <a class="figpopup" href="/books/NBK91457/table/bietti-cd.T.cyp4v2_pathogenic_variants_d/?report=objectonly" target="object" rid-figpopup="figbietticdTcyp4v2pathogenicvariantsd" rid-ob="figobbietticdTcyp4v2pathogenicvariantsd">c.802-8_810delinsGC</a> and <a class="figpopup" href="/books/NBK91457/table/bietti-cd.T.cyp4v2_pathogenic_variants_d/?report=objectonly" target="object" rid-figpopup="figbietticdTcyp4v2pathogenicvariantsd" rid-ob="figobbietticdTcyp4v2pathogenicvariantsd">c.1091-2A&#x0003e;G</a> had more severe disease based on electrophysiologic testing; namely, lower EOG Arden indices and higher likelihood of a nonrecordable scotopic ffERG and 30-Hz flicker ERG when compared with individuals with pathogenic variants in the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>. The level of visual loss in BCD is related to the severity of retinal thinning [<a class="bk_pop" href="#bietti-cd.REF.lai.2007.5212">Lai et al 2007</a>].</p><p>The variant <a class="figpopup" href="/books/NBK91457/table/bietti-cd.T.cyp4v2_pathogenic_variants_d/?report=objectonly" target="object" rid-figpopup="figbietticdTcyp4v2pathogenicvariantsd" rid-ob="figobbietticdTcyp4v2pathogenicvariantsd">c.332T&#x0003e;C</a> (p.Ile111Thr) has only been reported in European individuals. One individual with this <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was reported to have an unusual central and paracentral corneal distribution of crystalline deposits, without limbic involvement. Two unaffected elderly <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> carriers from the same family were also found to have multiple subepithelial and anterior stromal crystalline deposits in the central and paracentral cornea. This was absent in the young heterozygous carriers. This could suggest a dose-dependent <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of this variant [<a class="bk_pop" href="#bietti-cd.REF.garc_agarc_a.2013.1002">Garc&#x000ed;a-Garc&#x000ed;a et al 2013</a>].</p><p>Of note, individuals without two identified pathogenic <i>CYP4V2</i> variants were phenotypically indistinguishable from those found to have pathogenic variants [<a class="bk_pop" href="#bietti-cd.REF.astuti.2015.14">Astuti et al 2015</a>].</p><p>The high degree of clinical variability in BCD suggests the influence of factors other than the primary <i>CYP4V2</i> defect. The uncommon reports of regional retinal involvement may represent disease caused by pathogenic variants that are associated with retention of either a small amount of functional <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a> or other modifying factors. Inflammatory or infectious disease (e.g., sinusitis) may be associated with worsening of disease, and treatment with antibiotics, steroids, and surgery may lead to short-term improvement in visual symptoms as well as visual acuity and visual fields, suggesting the possibility of an inflammatory component to the disease [<a class="bk_pop" href="#bietti-cd.REF.lockhart.2018.187">Lockhart et al 2018</a>].</p></div><div id="bietti-cd.Prevalence"><h3>Prevalence</h3><p>While BCD is generally considered to be a rare disease, it may be underdiagnosed. For example, in a study done by <a class="bk_pop" href="#bietti-cd.REF.mataftsi.2004.416">Mataftsi et al [2004]</a>, approximately 10% of persons with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> retinitis pigmentosa (RP) were also diagnosed with BCD. Furthermore, it has been estimated that up to 3% of individuals initially diagnosed with RP can be accounted for by BCD [<a class="bk_pop" href="#bietti-cd.REF.mataftsi.2004.416">Mataftsi et al 2004</a>]. According to <a class="bk_pop" href="#bietti-cd.REF.hartong.2006.1795">Hartong et al [2006]</a>, worldwide prevalence of RP was one in 4,000, with autosomal recessive RP accounting for 50%-60% of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. This implies a prevalence of BCD of up to 1:67,000, representing almost 5,000 individuals in the US alone.</p><p>BCD appears to be more common in people of East Asian descent, particularly the Chinese and Japanese [<a class="bk_pop" href="#bietti-cd.REF.hu.1983.39">Hu 1983</a>, <a class="bk_pop" href="#bietti-cd.REF.tian.2015.465">Tian et al 2015</a>]; however, individuals of European, Middle Eastern, African, and North and South American origin have also been reported [<a class="bk_pop" href="#bietti-cd.REF.mataftsi.2004.416">Mataftsi et al 2004</a>, <a class="bk_pop" href="#bietti-cd.REF.lin.2005.e38">Lin et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.lai.2007.5212">Lai et al 2007</a>, <a class="bk_pop" href="#bietti-cd.REF.zenteno.2008.313">Zenteno et al 2008</a>, <a class="bk_pop" href="#bietti-cd.REF.garc_agarc_a.2013.1002">Garc&#x000ed;a-Garc&#x000ed;a et al 2013</a>, <a class="bk_pop" href="#bietti-cd.REF.astuti.2015.14">Astuti et al 2015</a>].</p></div></div><div id="bietti-cd.Genetically_Related_Allelic_Di"><h2 id="_bietti-cd_Genetically_Related_Allelic_Di_">Genetically Related (Allelic) Disorders</h2><p>A single report identified pathogenic variants in <i>CYP4V2</i> and <i>CTNNA1</i> in individuals with <a href="/books/n/gene/lca-ov/">Leber congenital amaurosis</a> [<a class="bk_pop" href="#bietti-cd.REF.jinda.2017.2413">Jinda et al 2017</a>]; however, this association requires further elucidation in larger cohorts.</p><p>A novel <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>CYP4V2</i> variant (c.362C&#x0003e;A:Ser121Tyr) in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 3 has been reported with a choroideremia-like <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in an individual of Japanese descent [<a class="bk_pop" href="#bietti-cd.REF.katagiri.2017.286">Katagiri et al 2017</a>].</p><p>A common <a class="def" href="/books/n/gene/glossary/def-item/single-nucleotide-variant/">single-nucleotide variant</a> (SNV) of <i>CYP4V2</i>, c.775C&#x0003e;A (p.Gln259Lys), has emerged as a risk factor in deep venous thromboembolism (DVT) [<a class="bk_pop" href="#bietti-cd.REF.bezemer.2008.1306">Bezemer et al 2008</a>, <a class="bk_pop" href="#bietti-cd.REF.li.2009.1802">Li et al 2009</a>, <a class="bk_pop" href="#bietti-cd.REF.tr_gou_t.2009.5298">Tr&#x000e9;gou&#x000eb;t et al 2009</a>]. The association was confirmed in a recent meta-analysis of five replication cohorts [<a class="bk_pop" href="#bietti-cd.REF.austin.2011.489">Austin et al 2011</a>]. c.775C&#x0003e;A is in linkage disequilibrium with SNVs in <i>F11</i> (encoding factor XI) and <i>KLKB1</i> (encoding pre-kallikrein), proteins known to be involved in coagulation. Initially this was thought to explain, at least in part, the observed association of c.775C&#x0003e;A with DVT; however, more detailed genetic analysis indicated that persons possessing the A-C-T haplotype corresponding to <i>CYP4V2</i> c.775C&#x0003e;A, <i>F11</i>
<a href="/projects/SNP/snp_ref.cgi?rs=2036914" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs2036914</a>, and <i>F11</i>
<a href="/projects/SNP/snp_ref.cgi?rs=2289252" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs2289252</a> were at highest risk for DVT (odds ratio: 1.55-1.57) [<a class="bk_pop" href="#bietti-cd.REF.li.2009.1802">Li et al 2009</a>], indicating an essential modulating influence of <i>CYP4V2</i> c.775C&#x0003e;A variant on the two more directly acting <i>F11</i> SNVs.</p></div><div id="bietti-cd.Differential_Diagnosis"><h2 id="_bietti-cd_Differential_Diagnosis_">Differential Diagnosis</h2><p><a href="/books/n/gene/rp-overview/"><b>Retinitis pigmentosa</b></a><b>.</b> The clinical symptoms and findings on visual field testing and electrophysiologic studies in Bietti crystalline dystrophy (BCD) are similar to those of other forms of retinal degeneration that fall under the category of retinitis pigmentosa and allied disorders.</p><p>Crystalline deposits in the retina may be associated with the following:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/ph1/">Primary hyperoxaluria type 1</a> and <a href="/books/n/gene/ph2/">primary hyperoxaluria type 2</a></div></li><li class="half_rhythm"><div><a href="/books/n/gene/ctns/">Cystinosis</a>, particularly the more benign adolescent presentation</div></li><li class="half_rhythm"><div>Sj&#x000f6;gren-Larsson syndrome (OMIM <a href="http://omim.org/entry/270200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">270200</a>)</div></li><li class="half_rhythm"><div>Drug toxicity (e.g., tamoxifen, the anesthetic methoxyflurane, the oral tanning agent canthaxanthine)</div></li><li class="half_rhythm"><div>Drug abuse (talc retinopathy)</div></li></ul></div><div id="bietti-cd.Management"><h2 id="_bietti-cd_Management_">Management</h2><div id="bietti-cd.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with Bietti crystalline dystrophy (BCD), the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div>Fundoscopic examination</div></li><li class="half_rhythm"><div>Full-field electroretinogram (ffERG) to establish a baseline</div></li><li class="half_rhythm"><div>Visual field testing (perimetry) to evaluate the degree of visual field constriction or presence of scotomas and to establish a baseline</div></li><li class="half_rhythm"><div>Optical coherence tomography to evaluate for complications such as choroidal neovascularization (CNV) or macular hole formation</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="bietti-cd.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>No specific treatment for BCD currently exists; however, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals should be referred to services specific to those with vision impairment:</p><ul><li class="half_rhythm"><div>Low-vision specialists can prescribe low-vision aids/devices to optimize remaining vision.</div></li><li class="half_rhythm"><div>State services for the blind or organizations/professionals trained to work with the visually impaired provide access to services related to employment, education, and counseling regarding the psychosocial adaptation to visual loss.</div></li></ul><p>Note: CNV is uncommon in BCD. Laser photocoagulation is not usually considered for CNV in inherited forms of retinal degeneration and has recently been superseded by the use of antivascular endothelial growth factor (anti-VEGF) therapy in a fashion similar to its use in age-related macular dystrophy.</p></div><div id="bietti-cd.Surveillance"><h3>Surveillance</h3><p>Ophthalmologic examination is recommended every one to two years to monitor disease progression. Examination should include visual field testing particularly as it relates to determination of driving eligibility and eligibility for government programs and/or disability.</p><p>Affected individuals should be aware of the possibility of CNV and the option of self-monitoring using an Amsler grid under direction of their primary care ophthalmologist.</p></div><div id="bietti-cd.Evaluation_of_Relatives_at_Ris"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#bietti-cd.Related_Genetic_Counseling_Iss">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="bietti-cd.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="bietti-cd.Genetic_Counseling"><h2 id="_bietti-cd_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="bietti-cd.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Bietti crystalline dystrophy (BCD) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="bietti-cd.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>CYP4V2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Unless an individual with Bietti crystalline dystrophy has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, his/her offspring will be obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>CYP4V2</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>CYP4V2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="bietti-cd.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>CYP4V2</i> pathogenic variants in the family.</p></div><div id="bietti-cd.Related_Genetic_Counseling_Iss"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="bietti-cd.Prenatal_Testing_and_Preimplan"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>CYP4V2</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for Bietti crystalline dystrophy are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="bietti-cd.Resources"><h2 id="_bietti-cd_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Eye Institute</b></div><div>31 Center Drive</div><div>MSC 2510</div><div>Bethesda MD 20892-2510</div><div><b>Phone:</b> 301-496-5248</div><div><b>Email:</b> 2020@nei.nih.gov</div><div><a href="https://nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/biettis-crystalline-dystrophy" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bietti's Crystalline Dystrophy</a></div></li><li class="half_rhythm"><div><b>American Council of the Blind (ACB)</b></div><div>2200 Wilson Boulevard</div><div>Suite 650</div><div>Arlington VA 22201</div><div><b>Phone:</b> 800-424-8666 (toll-free); 202-467-5081</div><div><b>Fax:</b> 202-467-5085</div><div><b>Email:</b> info@acb.org</div><div><a href="http://www.acb.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.acb.org</a></div></li><li class="half_rhythm"><div><b>Foundation Fighting Blindness</b></div><div>7168 Columbia Gateway Drive</div><div>Suite 100</div><div>Columbia MD 21046</div><div><b>Phone:</b> 800-683-5555 (toll-free); 800-683-5551 (toll-free TDD); 410-423-0600</div><div><b>Email:</b> info@fightblindness.org</div><div><a href="https://www.fightingblindness.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.fightingblindness.org</a></div></li><li class="half_rhythm"><div><b>National Federation of the Blind (NFB)</b></div><div>200 East Wells Street</div><div>(at Jernigan Place)</div><div>Baltimore MD 21230</div><div><b>Phone:</b> 410-659-9314</div><div><b>Fax:</b> 410-685-5653</div><div><b>Email:</b> pmaurer@nfb.org</div><div><a href="http://www.nfb.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nfb.org</a></div></li><li class="half_rhythm"><div><b>Prevent Blindness America</b></div><div>211 West Wacker Drive</div><div>Suite 1700</div><div>Chicago IL 60606</div><div><b>Phone:</b> 800-331-2020 (toll-free)</div><div><b>Email:</b> info@preventblindness.org</div><div><a href="http://www.preventblindness.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.preventblindness.org</a></div></li><li class="half_rhythm"><div><b>Retina International</b></div><div>Retina Suisse</div><div>Ausstellungsstrasse 36</div><div> Zurich CH-8005</div><div>Switzerland</div><div><b>Phone:</b> +41 (0) 44 444 1077</div><div><b>Fax:</b> +41 (0) 44 444 1070</div><div><b>Email:</b> christina.fasser@retina-international.org</div><div><a href="http://www.retina-international.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.retina-international.org</a></div></li></ul></div><div id="bietti-cd.Molecular_Genetics"><h2 id="_bietti-cd_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="bietti-cd.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Bietti Crystalline Dystrophy: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK91457/table/bietti-cd.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bietti-cd.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_bietti-cd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_bietti-cd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_bietti-cd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_bietti-cd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_bietti-cd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_bietti-cd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_bietti-cd.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/285440" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>CYP4V2</i></a></td><td headers="hd_b_bietti-cd.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=285440" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">4q35<wbr style="display:inline-block"></wbr>​.1-q35.2</a></td><td headers="hd_b_bietti-cd.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q6ZWL3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cytochrome P450 4V2</a></td><td headers="hd_b_bietti-cd.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/CYP4V2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CYP4V2 @ LOVD</a></td><td headers="hd_b_bietti-cd.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=CYP4V2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CYP4V2</a></td><td headers="hd_b_bietti-cd.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=CYP4V2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">CYP4V2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="bietti-cd.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="bietti-cd.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Bietti Crystalline Dystrophy (<a href="/omim/210370,608614" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK91457/table/bietti-cd.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bietti-cd.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/210370" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">210370</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BIETTI CRYSTALLINE CORNEORETINAL DYSTROPHY; BCD</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/608614" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">608614</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CYTOCHROME P450, FAMILY 4, SUBFAMILY V, POLYPEPTIDE 2; CYP4V2</td></tr></tbody></table></div></div><div id="bietti-cd.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Though the biochemical basis of BCD remains unknown, findings suggest that BCD may result from a systemic abnormality in lipid metabolism. There also have been reports of a missing 32-kd fatty-acid binding protein with a high affinity for fatty acids: docosahexaenoic acid (DHA; 22:6n-3), &#x003b1;-linolenic acid (18:3n-3), and palmitic acid (16:0) in the lymphocytes of persons with BCD compared to controls [<a class="bk_pop" href="#bietti-cd.REF.lee.1998.143">Lee et al 1998</a>]. Metabolic studies of fibroblasts and lymphocytes cultured from individuals with BCD exhibited altered lipid metabolism, with decreased synthesis of &#x003c9;-3 polyunsaturated fatty acids (PUFAs) (e.g., eicosapentaenoic acid [EPA; 20:5n-3] and DHA) from &#x003b1;-linolenic acid compared to controls [<a class="bk_pop" href="#bietti-cd.REF.lee.2001.1707">Lee et al 2001</a>]. <i>CYP4V2</i> has been proposed to play a role in ocular inflammation [<a class="bk_pop" href="#bietti-cd.REF.nakano.2014.247">Nakano et al 2014</a>] and worsening of disease has been associated with extraocular infection (e.g., severe sinusitis) [<a class="bk_pop" href="#bietti-cd.REF.lockhart.2018.187">Lockhart et al 2018</a>].</p><p>Free fatty acid profiling revealed significantly altered fatty acid concentrations in the serum of persons with BCD: stearic acid (18:0) was elevated and oleic acid (18:1n-9) was lowered in persons with BCD compared to controls [<a class="bk_pop" href="#bietti-cd.REF.lai.2010.1092">Lai et al 2010</a>].</p><p>In addition to ocular tissues, transmission electron microscopy showed crystalline material of unknown lipid composition in lymphoblasts and fibroblasts of persons with BCD [<a class="bk_pop" href="#bietti-cd.REF.welch.1977.164">Welch 1977</a>].</p><p><b>Gene structure.</b>
<i>CYP4V2</i> spans 19 kb and comprises 11 exons [<a class="bk_pop" href="#bietti-cd.REF.li.2004.817">Li et al 2004</a>]. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK91457/#bietti-cd.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> A wide range of <i>CYP4V2</i> pathogenic variants (nearly 100) have now been described in individuals with BCD.</p><p>Several common variants are specific to geographic or ethnic backgrounds, such as c.802-8_810delinsGC in East Asian individuals, p.Met66Arg in individuals of South Asian ancestry, and p.Ile111Thr in European individuals [<a class="bk_pop" href="#bietti-cd.REF.halford.2014.1174">Halford et al 2014</a>]. These variations have been attributed to a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> [<a class="bk_pop" href="#bietti-cd.REF.zhang.2018.700">Zhang et al 2018</a>].</p><p>The most frequent <i>CYP4V2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, c.802-8_810delinsGC, results in the skipping of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7 due to <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of the 3' <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> acceptor site of <a class="def" href="/books/n/gene/glossary/def-item/intron/">intron</a> 6. Eight nucleotides of the 3' end of intron 6 and nine from the 5' end of exon 7 are deleted along with an <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> of GC [<a class="bk_pop" href="#bietti-cd.REF.lee.2005.3812">Lee et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.shan.2005.738">Shan et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.wada.2005.894">Wada et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.lai.2007.5212">Lai et al 2007</a>, <a class="bk_pop" href="#bietti-cd.REF.chung.2013.447">Chung et al 2013</a>, <a class="bk_pop" href="#bietti-cd.REF.zhang.2018.700">Zhang et al 2018</a>].</p><p>Two other disease-associated variants, c.1091-2A&#x0003e;G and c.1226-6_1235del16 (a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> spanning the splice acceptor site for <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 9), result in skipping of exons 9 and 10, respectively [<a class="bk_pop" href="#bietti-cd.REF.li.2004.817">Li et al 2004</a>, <a class="bk_pop" href="#bietti-cd.REF.shan.2005.738">Shan et al 2005</a>].</p><p>Numerous disease-associated variants have been described. The majority of described variants are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, while the remaining variants include <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, small insertions or deletions, and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> defects. One large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> encompassing <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 8 and an additional deletion including all of <i>CYP4V2</i> and several other genes has been reported [<a class="bk_pop" href="#bietti-cd.REF.li.2004.817">Li et al 2004</a>, <a class="bk_pop" href="#bietti-cd.REF.lee.2005.3812">Lee et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.lin.2005.e38">Lin et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.shan.2005.738">Shan et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.wada.2005.894">Wada et al 2005</a>, <a class="bk_pop" href="#bietti-cd.REF.lai.2007.5212">Lai et al 2007</a>, <a class="bk_pop" href="#bietti-cd.REF.hardwick.2008.2263">Hardwick 2008</a>, <a class="bk_pop" href="#bietti-cd.REF.zenteno.2008.313">Zenteno et al 2008</a>, <a class="bk_pop" href="#bietti-cd.REF.xiao.2011.181">Xiao et al 2011</a>, <a class="bk_pop" href="#bietti-cd.REF.astuti.2015.14">Astuti et al 2015</a>, <a class="bk_pop" href="#bietti-cd.REF.tian.2015.465">Tian et al 2015</a>, <a class="bk_pop" href="#bietti-cd.REF.zhang.2018.700">Zhang et al 2018</a>].</p><div id="bietti-cd.T.cyp4v2_pathogenic_variants_d" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p><i>CYP4V2</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK91457/table/bietti-cd.T.cyp4v2_pathogenic_variants_d/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__bietti-cd.T.cyp4v2_pathogenic_variants_d_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.197T&#x0003e;G</td><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Met66Arg</td><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/query.fcgi?cmd=Search&#x00026;db=Nucleotide&#x00026;term=NM_207352.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_207352<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/entrez/query.fcgi?cmd=Search&#x00026;db=protein&#x00026;term=NP_997235.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_997235<wbr style="display:inline-block"></wbr>​.3</a></td></tr><tr><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.327+1G&#x0003e;A<br />(IVS2+1G&#x0003e;A)</td><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 2</td></tr><tr><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.332T&#x0003e;C</td><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile111Thr</td></tr><tr><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.802-8_810delinsGC&#x000a0;<sup>3</sup><br />(IVS6-8del/insGC)</td><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td></tr><tr><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1091-2A&#x0003e;G<br />(IVS8-2A&#x0003e;G)</td><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 4</td></tr><tr><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1226-6_1235del16&#x000a0;<sup>5</sup><br />(IVS9-6del)</td><td headers="hd_h_bietti-cd.T.cyp4v2_pathogenic_variants_d_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 5</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="bietti-cd.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="bietti-cd.TF.2.2"><p class="no_margin">Skipping of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2, resulting in a frameshift in which the exon 1 sequence is followed by four novel amino acids and a premature terminating [<a class="bk_pop" href="#bietti-cd.REF.li.2004.817">Li et al 2004</a>]</p></div></dd><dt>3. </dt><dd><div id="bietti-cd.TF.2.3"><p class="no_margin">Skipping of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 7, which encodes 62 amino acids [<a class="bk_pop" href="#bietti-cd.REF.wada.2005.894">Wada et al 2005</a>]</p></div></dd><dt>4. </dt><dd><div id="bietti-cd.TF.2.4"><p class="no_margin">Skipping of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 9, which encodes 62 amino acids</p></div></dd><dt>5. </dt><dd><div id="bietti-cd.TF.2.5"><p class="no_margin">Skipping of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 10, which encodes 60 amino acids [<a class="bk_pop" href="#bietti-cd.REF.shan.2005.738">Shan et al 2005</a>]</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The cytochrome P450 4V2 protein (CYP4V2) is 525 amino acids. This protein is a member of the CYP superfamily of heme-containing monooxygenases. CYP4V2 is a fatty acid oxidase, with preferential activity for &#x003c9;-hydroxylation of saturated, medium-chain fatty acids [<a class="bk_pop" href="#bietti-cd.REF.nakano.2009.2119">Nakano et al 2009</a>]. Homology modeling predicts that the CYP4V2 structure contains a transmembrane segment located near the amino terminus with a globular structural <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> following that is typical of cytochrome P450 enzymes. The globular domain of CYP4V2 comprises 18 helices and &#x003b2; structural elements [<a class="bk_pop" href="#bietti-cd.REF.li.2004.817">Li et al 2004</a>].</p><p>Recent studies support a role for CYP4V2 function in controlling intracellular lipid metabolisms [<a class="bk_pop" href="#bietti-cd.REF.li.2017.8841">Li et al 2017</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Variants predicted to be <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> resulting in loss of enzyme activity have been associated with disease. Similarly, several amino acid deletions and substitutions would be predicted to be deleterious based on conservation studies with other CYP4 enzymes [<a class="bk_pop" href="#bietti-cd.REF.li.2004.817">Li et al 2004</a>].</p><p>Exon-skipping pathogenic variants, namely c.802-8_810delinsGC, are associated with more severe forms of the disease than are pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants [<a class="bk_pop" href="#bietti-cd.REF.lai.2007.5212">Lai et al 2007</a>, <a class="bk_pop" href="#bietti-cd.REF.zhang.2018.700">Zhang et al 2018</a>].</p><p>Defects in the catalytic function of this enzyme lead to altered fatty acid metabolism; the endogenous substrate(s) have yet to be identified.</p></div></div><div id="bietti-cd.References"><h2 id="_bietti-cd_References_">References</h2><div id="bietti-cd.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.astuti.2015.14">Astuti GDN, Sun V, Bauwens M, Zobor D, Leroy BP, Omar A, Jurklies B, Lopez I, Ren H, Yazar V, Hamel C, Kellner U, Wissinger B, Kohl S, Baere ED, Collin RWJ, Koenekoop RK. Novel insights into the molecular pathogenesis of CYP4V2-associated Bietti's retinal dystrophy. <span><span class="ref-journal">Mol Genet Genomic Med. </span>2015;<span class="ref-vol">3</span>:14–29.</span> [<a href="/pmc/articles/PMC4299712/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4299712</span></a>] [<a href="/pubmed/25629076" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25629076</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.atmaca.2007.839">Atmaca LS, Muftuoglu O, Atmaca-Sonmez P. Peripapillary choroidal neovascularization in Bietti crystalline retinopathy. <span><span class="ref-journal">Eye (Lond). </span>2007;<span class="ref-vol">21</span>:839–42.</span> [<a href="/pubmed/17173010" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17173010</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.austin.2011.489">Austin H, De Staercke C, Lally C, Bezemer ID, Rosendaal FR, Hooper WC. New gene variants associated with venous thrombosis: a replication study in white and black Americans. <span><span class="ref-journal">J Thromb Haemost. </span>2011;<span class="ref-vol">9</span>:489–95.</span> [<a href="/pmc/articles/PMC4532311/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4532311</span></a>] [<a href="/pubmed/21232005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21232005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.bezemer.2008.1306">Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. <span><span class="ref-journal">JAMA. </span>2008;<span class="ref-vol">299</span>:1306–14.</span> [<a href="/pubmed/18349091" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18349091</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.chen.2008.237">Chen H, Zhang M, Huang S, Wu D. Functional and clinical findings in 3 female siblings with crystalline retinopathy. <span><span class="ref-journal">Doc Ophthalmol. </span>2008;<span class="ref-vol">116</span>:237–43.</span> [<a href="/pubmed/17962988" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17962988</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.chung.2013.447">Chung JK, Shin JH, Jeon BR, Ki CS, Park TK. Optical coherence tomographic findings of crystal deposits in the lens and cornea in Bietti crystalline corneoretinopathy associated with mutation in the CYP4V2 gene. <span><span class="ref-journal">Jpn J Ophthalmol. </span>2013;<span class="ref-vol">57</span>:447–50.</span> [<a href="/pubmed/23793346" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23793346</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.garc_agarc_a.2013.1002">Garc&#x000ed;a-Garc&#x000ed;a GP, L&#x000f3;pez-Garrido MP, Mart&#x000ed;nez-Rubio M, Moya-Moya MA, Belmonte-Mart&#x000ed;nez J, Escribano J. Genotype-phenotype analysis of Bietti crystalline dystrophy in a family with the CYP4V2 Ile111Thr mutation. <span><span class="ref-journal">Cornea. </span>2013;<span class="ref-vol">32</span>:1002–8.</span> [<a href="/pubmed/23538635" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23538635</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.gupta.2011.59">Gupta B, Parvizi S, Mohamed MD. Bietti crystalline dystrophy and choroidal neovascularisation. <span><span class="ref-journal">Int Ophthalmol. </span>2011;<span class="ref-vol">31</span>:59–61.</span> [<a href="/pubmed/20972604" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20972604</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.halford.2014.1174">Halford S, Liew G, Mackay DS, Sergouniotis PI, Holt R, Broadgate S, Volpi EV, Ocaka L, Pobson AG, Holder GE, Moore AT, Michaelides M, Webster AR. Detailed phenotypic and genotypic characterization of Bietti crystalline dystrophy. <span><span class="ref-journal">Ophthalmology. </span>2014;<span class="ref-vol">121</span>:1174–84.</span> [<a href="/pubmed/24480711" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24480711</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.hardwick.2008.2263">Hardwick JP. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. <span><span class="ref-journal">Biochem Pharmacol. </span>2008;<span class="ref-vol">75</span>:2263–75.</span> [<a href="/pubmed/18433732" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18433732</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.hartong.2006.1795">Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. <span><span class="ref-journal">Lancet. </span>2006;<span class="ref-vol">368</span>:1795–809.</span> [<a href="/pubmed/17113430" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17113430</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.hu.1983.39">Hu DN. Ophthalmic genetics in China. <span><span class="ref-journal">Ophthal Paediat Genet. </span>1983;<span class="ref-vol">2</span>:39–45.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.jinda.2017.2413">Jinda W, Taylor TD, Suzuki Y, Thongnoppakhun W, Limwongse C, Lertrit P, Trinavarat A, Atchaneeyasakul LO. Whole exome sequencing in eight Thai patients with Leber congenital amaurosis reveals mutations in the CTNNA1 and CYP4V2 genes. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2017;<span class="ref-vol">58</span>:2413–20.</span> [<a href="/pubmed/28453600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28453600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.kaiserkupfer.1994.569">Kaiser-Kupfer MI, Chan CC, Markello TC, Crawford MA, Caruso RC, Csaky KG, Guo J, Gahl WA. Clinical biochemical and pathologic correlations in Bietti's crystalline dystrophy. <span><span class="ref-journal">Am J Ophthalmol. </span>1994;<span class="ref-vol">118</span>:569–82.</span> [<a href="/pubmed/7977570" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7977570</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.katagiri.2017.286">Katagiri S, Hayashi T, Gekka T, Tsuneoka H. A novel homozygous CYP4V2 variant (p.S121Y) associated with a choroideremia-like phenotype. <span><span class="ref-journal">Ophthalmic Genet. </span>2017;<span class="ref-vol">38</span>:286–7.</span> [<a href="/pubmed/27348340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27348340</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.kojima.2012.390">Kojima H, Otani A, Ogino K, Nakagawa S, Makiyama Y, Kurimoto M, Guo C, Yoshimura N. Outer retinal circular structures in patients with Bietti crystalline retinopathy. <span><span class="ref-journal">Br J Ophthalmol. </span>2012;<span class="ref-vol">96</span>:390–3.</span> [<a href="/pubmed/21803923" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21803923</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.lai.2010.1092">Lai TY, Chu KO, Chan KP, Ng TK, Yam GH, Lam DS, Pang CP. Alterations in serum fatty acid concentrations and desaturase activities in Bietti crystalline dystrophy unaffected by CYP4V2 genotypes. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2010;<span class="ref-vol">51</span>:1092–7.</span> [<a href="/pubmed/19797200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19797200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.lai.2007.5212">Lai TY, Ng TK, Tam PO, Yam GH, Ngai JW, Chan WM, Liu DT, Lam DS, Pang CP. Genotype phenotype analysis of Bietti's crystalline dystrophy in patients with CYP4V2 mutations. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2007;<span class="ref-vol">48</span>:5212–20.</span> [<a href="/pubmed/17962476" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17962476</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.lee.1998.143">Lee J, Jiao X, Hejtmancik JF, Kaiser-Kupfer M, Chader GJ. Identification, isolation, and characterization of a 32-kDa fatty acid-binding protein missing from lymphocytes in humans with Bietti crystalline dystrophy (BCD). <span><span class="ref-journal">Mol Genet Metab. </span>1998;<span class="ref-vol">65</span>:143–54.</span> [<a href="/pubmed/9787106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9787106</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.lee.2001.1707">Lee J, Jiao X, Hejtmancik JF, Kaiser-Kupfer M, Gahl WA, Markello TC, Guo J, Chader GJ. The metabolism of fatty acids in human Bietti crystalline dystrophy. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2001;<span class="ref-vol">42</span>:1707–14.</span> [<a href="/pubmed/11431432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11431432</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.lee.2005.3812">Lee KY, Koh AH, Aung T, Yong VH, Yeung K, Ang CL, Vithana EN. Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations. <span><span class="ref-journal">Invest Ophthalmol Vis Sci. </span>2005;<span class="ref-vol">46</span>:3812–6.</span> [<a href="/pubmed/16186368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16186368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.li.2004.817">Li A, Jiao X, Munier FL, Schorderet DF, Yao W, Iwata F, Hayakawa M, Kanai A, Shy Chen M, Alan Lewis R, Heckenlively J, Weleber RG, Traboulsi EI, Zhang Q, Xiao X, Kaiser-Kupfer M, Sergeev YV, Hejtmancik JF. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">74</span>:817–26.</span> [<a href="/pmc/articles/PMC1181977/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1181977</span></a>] [<a href="/pubmed/15042513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15042513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.li.2015.2074">Li Q, Li Y, Zang X, Xu Z, Zhu X, Ma K, She H, Peng X. Utilization of fundus autofluorescence, spectral domain optical coherence tomography, and enhanced depth imaging in the characterization of Bietti crystalline dystrophy in different stages. <span><span class="ref-journal">Retina. </span>2015;<span class="ref-vol">35</span>:2074–84.</span> [<a href="/pubmed/25978730" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25978730</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.li.2017.8841">Li S, Li Q, Kong Y, Wu S, Cui Q, Zhang M, Zhang SO. Specific regulation of thermosensitive lipid droplet fusion by a nuclear hormone receptor pathway. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2017;<span class="ref-vol">114</span>:8841–6.</span> [<a href="/pmc/articles/PMC5565433/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5565433</span></a>] [<a href="/pubmed/28760992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28760992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.li.2009.1802">Li Y, Bezemer ID, Rowland CM, Tong CH, Arellano AR, Catanese JJ, Devlin JJ, Reitsma PH, Bare LA, Rosendaal FR. Genetic variants associated with deep vein thrombosis: the F11 locus. <span><span class="ref-journal">J Thromb Haemost. </span>2009;<span class="ref-vol">7</span>:1802–8.</span> [<a href="/pubmed/19583818" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19583818</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.lin.2005.e38">Lin J, Nishiguchi KM, Nakamura M, Dryja TP, Berson EL, Miyake Y. Recessive mutations in the CYP4V2 gene in East Asian and Middle Eastern patients with Bietti crystalline corneoretinal dystrophy. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:e38.</span> [<a href="/pmc/articles/PMC1736086/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1736086</span></a>] [<a href="/pubmed/15937078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15937078</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.lockhart.2018.187">Lockhart CM, Smith TB, Yang P, Naidu M, Rettie AE, Nath A, Weleber R, Kelly EJ. Longitudinal characterisation of function and structure of Bietti crystalline dystrophy: report on a novel homozygous mutation in CYP4V2. <span><span class="ref-journal">Br J Ophthalmol. </span>2018;<span class="ref-vol">102</span>:187–94.</span> [<a href="/pmc/articles/PMC6208130/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6208130</span></a>] [<a href="/pubmed/28698241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28698241</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.mansour.2007.680">Mansour AM, Uwaydat SH, Chan CC. Long-term follow-up in Bietti crystalline dystrophy. <span><span class="ref-journal">Eur J Ophthalmol. </span>2007;<span class="ref-vol">17</span>:680–2.</span> [<a href="/pmc/articles/PMC2507722/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2507722</span></a>] [<a href="/pubmed/17671952" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17671952</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.mataftsi.2004.416">Mataftsi A, Zografos L, Mill&#x000e1; E, Secr&#x000e9;tan M, Munier FL. Bietti's crystalline corneoretinal dystrophy: a cross-sectional study. <span><span class="ref-journal">Retina. </span>2004;<span class="ref-vol">24</span>:416–26.</span> [<a href="/pubmed/15187665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15187665</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.nakano.2009.2119">Nakano M, Kelly EJ, Rettie AE. Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase. <span><span class="ref-journal">Drug Metab Dispos. </span>2009;<span class="ref-vol">37</span>:2119–22.</span> [<a href="/pmc/articles/PMC2774980/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2774980</span></a>] [<a href="/pubmed/19661213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19661213</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.nakano.2014.247">Nakano M, Lockhart CM, Kelly EJ, Rettie AE. Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition. <span><span class="ref-journal">Drug Metab Rev. </span>2014;<span class="ref-vol">46</span>:247–60.</span> [<a href="/pmc/articles/PMC4676416/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4676416</span></a>] [<a href="/pubmed/24856391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24856391</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.padhi.2011.199">Padhi TR, Kesarwani S, Jalali S. Bietti crystalline retinal dystrophy with subfoveal neurosensory detachment and congenital tortuosity of retinal vessels: case report. <span><span class="ref-journal">Doc Ophthalmol. </span>2011;<span class="ref-vol">122</span>:199–206.</span> [<a href="/pubmed/21611771" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21611771</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.pennesi.2010.531">Pennesi ME, Weleber RG. High-resolution optical coherence tomography shows new aspects of Bietti crystalline retinopathy. <span><span class="ref-journal">Retina. </span>2010;<span class="ref-vol">30</span>:531–2.</span> [<a href="/pubmed/20139800" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20139800</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.rossi.2011.118">Rossi S, Testa F, Li A, Iorio VD, Zhang J, Gesualdo C, Corte MD, Chan CC, Fielding Hejtmancik J, Simonelli F. An atypical form of Bietti crystalline dystrophy. <span><span class="ref-journal">Ophthalmic Genet. </span>2011;<span class="ref-vol">32</span>:118–21.</span> [<a href="/pmc/articles/PMC3155699/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3155699</span></a>] [<a href="/pubmed/21385027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21385027</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.shan.2005.738">Shan M, Dong B, Zhao X, Wang J, Li G, Yang Y, Li Y. Novel mutations in the CYP4V2 gene associated with Bietti crystalline corneoretinal dystrophy. <span><span class="ref-journal">Mol Vis. </span>2005;<span class="ref-vol">11</span>:738–43.</span> [<a href="/pubmed/16179904" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16179904</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.takikawa.1992.969">Takikawa C, Miyake Y, Yamamoto S. Re-evaluation of crystalline retinopathy based on corneal findings. <span><span class="ref-journal">Folia Ophthalmol Jpn. </span>1992;<span class="ref-vol">43</span>:969–78.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.tian.2015.465">Tian R, Wang SR, Wang J, Chen YX. Novel CYP4V2 mutations associated with Bietti crystalline corneoretinal dystrophy in Chinese patients. <span><span class="ref-journal">Int J Ophthalmol. </span>2015;<span class="ref-vol">8</span>:465–9.</span> [<a href="/pmc/articles/PMC4458647/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4458647</span></a>] [<a href="/pubmed/26085992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26085992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.traboulsi.1987.156">Traboulsi EI, Faris BM. Crystalline retinopathy. <span><span class="ref-journal">Ann Ophthalmol. </span>1987;<span class="ref-vol">19</span>:156–8.</span> [<a href="/pubmed/3619268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3619268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.tr_gou_t.2009.5298">Tr&#x000e9;gou&#x000eb;t DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, Galan P, Drouet L, Zelenika D, Juhan-Vague I, Alessi MC, Tiret L, Lathrop M, Emmerich J, Morange PE. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. <span><span class="ref-journal">Blood. </span>2009;<span class="ref-vol">113</span>:5298–303.</span> [<a href="/pubmed/19278955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19278955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.usui.2001.395">Usui T, Tanimoto N, Takagi M, Hasegawa S, Abe H. Rod and cone a-waves in three cases of Bietti crystalline chorioretinal dystrophy. <span><span class="ref-journal">Am J Ophthalmol. </span>2001;<span class="ref-vol">132</span>:395–402.</span> [<a href="/pubmed/11530054" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11530054</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.wada.2005.894">Wada Y, Itabashi T, Sato H, Kawamura M, Tada A, Tamai M. Screening for mutations in CYP4V2 gene in Japanese patients with Bietti's crystalline corneoretinal dystrophy. <span><span class="ref-journal">Am J Ophthalmol. </span>2005;<span class="ref-vol">139</span>:894–9.</span> [<a href="/pubmed/15860296" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15860296</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.welch.1977.164">Welch RB. Bietti's tapetoretinal degeneration with marginal corneal dystrophy crystalline retinopathy. <span><span class="ref-journal">Trans Am Ophthalmol Soc. </span>1977;<span class="ref-vol">75</span>:164–79.</span> [<a href="/pmc/articles/PMC1311548/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1311548</span></a>] [<a href="/pubmed/306693" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 306693</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.weleber.1991">Weleber RG, Wilson DJ. Bietti's crystalline dystrophy of the cornea and retina. In: Heckenlively JR, Arden GB, eds. <em>Principles and Practice of Clinical Electrophysiology of Vision.</em> St Louis, MO: Mosby Year Book; 1991:683-91.</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.wilson.1989.213">Wilson DJ, Weleber RG, Klein ML, Welch RB, Green WR. Bietti's crystalline dystrophy. A clinicopathologic correlative study. <span><span class="ref-journal">Arch Ophthalmol. </span>1989;<span class="ref-vol">107</span>:213–21.</span> [<a href="/pubmed/2783846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2783846</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.xiao.2011.181">Xiao X, Mai G, Li S, Guo X, Zhang Q. Identification of CYP4V2 mutation in 21 families and overview of mutation spectrum in Bietti crystalline corneoretinal dystrophy. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2011;<span class="ref-vol">409</span>:181–6.</span> [<a href="/pubmed/21565171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21565171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.zenteno.2008.313">Zenteno JC, Ayala-Ramirez R, Graue-Wiechers F. Novel CYP4V2 gene mutation in a Mexican patient with Bietti's crystalline corneoretinal dystrophy. <span><span class="ref-journal">Curr Eye Res. </span>2008;<span class="ref-vol">33</span>:313–8.</span> [<a href="/pubmed/18398705" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18398705</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.zhang.2018.700">Zhang X, Xu K, Dong B, Peng X, Li Q, Jiang F, Xie Y, Tian L, Li Y. Comprehensive screening of CYP4V2 in a cohort of Chinese patients with Bietti crystalline dystrophy. <span><span class="ref-journal">Mol Vis. </span>2018;<span class="ref-vol">24</span>:700–11.</span> [<a href="/pmc/articles/PMC6204257/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6204257</span></a>] [<a href="/pubmed/30429639" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30429639</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.zhu.2009.660">Zhu Z, Ji X, Zhang J, Ke G. Posterior scleral reinforcement in the treatment of macular retinoschisis in highly myopic patients. <span><span class="ref-journal">Clin Exp Ophthalmol. </span>2009;<span class="ref-vol">37</span>:660–3.</span> [<a href="/pubmed/19788661" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19788661</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="bietti-cd.REF.zweifel.2009.1596">Zweifel SA, Engelbert M, Laud K, Margolis R, Spaide RF, Freund KB. Outer retinal tubulation: a novel optical coherence tomography finding. <span><span class="ref-journal">Arch Ophthalmol. </span>2009;<span class="ref-vol">127</span>:1596–602.</span> [<a href="/pubmed/20008714" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20008714</span></a>]</div></li></ul></div></div><div id="bietti-cd.Chapter_Notes"><h2 id="_bietti-cd_Chapter_Notes_">Chapter Notes</h2><div id="bietti-cd.Acknowledgments"><h3>Acknowledgments</h3><p>Supported in part by a Center Grant from Foundation Fighting Blindness, Columbia, MD, and an unrestricted grant from Research to Prevent Blindness (New York, NY)</p></div><div id="bietti-cd.Author_History"><h3>Author History</h3><p>Edward J Kelly, PhD; University of Washington School of Pharmacy (2012-2019)<br />Amanda Mitchell, MS, CGC (2019-present)<br />Krystle A Okialda, BS; University of Washington Department of Pharmaceutics (2012-2019)<br />Niamh B Stover, MS, CGC; Banner Health (2012-2019)<br />Mauricio Vargas, MD, PhD (2019-present)<br />Richard Weleber, MD, DABMG, FACMG (2012-present)<br />Paul Yang, MD, PhD (2019-present)</p></div><div id="bietti-cd.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>7 February 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>14 June 2012 (cd) Revision: prenatal testing available</div></li><li class="half_rhythm"><div>12 April 2012 (me) Review posted live</div></li><li class="half_rhythm"><div>31 October 2011 (ek) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK91457</span><span class="label">PMID: <a href="/pubmed/22497028" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">22497028</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/b-thal/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/bgd-biotin/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK91457&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK91457/?report=reader">PubReader</a></li><li><a href="/books/NBK91457/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK91457" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK91457" style="display:none" title="Cite this Page"><div class="bk_tt">Vargas M, Mitchell A, Yang P, et al. Bietti Crystalline Dystrophy. 2012 Apr 12 [Updated 2019 Feb 7]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK91457/pdf/Bookshelf_NBK91457.pdf">PDF version of this page</a> (219K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#bietti-cd.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#bietti-cd.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#bietti-cd.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#bietti-cd.Genetically_Related_Allelic_Di" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#bietti-cd.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#bietti-cd.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#bietti-cd.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#bietti-cd.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#bietti-cd.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#bietti-cd.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#bietti-cd.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=285440[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">CYP4V2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK91457+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=2884288" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=2884288" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=2884288" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=2884288" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31638456" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Presence of corneal crystals confirms an unusual presentation of Bietti's retinal dystrophy.</a><span class="source">[Ophthalmic Genet. 2019]</span><div class="brieflinkpop offscreen_noflow">Presence of corneal crystals confirms an unusual presentation of Bietti's retinal dystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Song WK, Clouston P, MacLaren RE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ophthalmic Genet. 2019 Oct; 40(5):461-465. Epub 2019 Oct 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22605929" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical and molecular findings in three Lebanese families with Bietti crystalline dystrophy: report on a novel mutation.</a><span class="source">[Mol Vis. 2012]</span><div class="brieflinkpop offscreen_noflow">Clinical and molecular findings in three Lebanese families with Bietti crystalline dystrophy: report on a novel mutation.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Haddad NM, Waked N, Bejjani R, Khoueir Z, Chouery E, Corbani S, Mégarbané A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Vis. 2012; 18:1182-8. Epub 2012 May 5.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31440027" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Current perspectives in Bietti crystalline dystrophy.</a><span class="source">[Clin Ophthalmol. 2019]</span><div class="brieflinkpop offscreen_noflow">Current perspectives in Bietti crystalline dystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">García-García GP, Martínez-Rubio M, Moya-Moya MA, Pérez-Santonja JJ, Escribano J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Ophthalmol. 2019; 13:1379-1399. Epub 2019 Jul 30.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27228076" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetics of Bietti Crystalline Dystrophy.</a><span class="source">[Asia Pac J Ophthalmol (Phila)....]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Genetics of Bietti Crystalline Dystrophy.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ng DS, Lai TY, Ng TK, Pang CP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Asia Pac J Ophthalmol (Phila). 2016 Jul-Aug; 5(4):245-52. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31725251" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">RPE65</i>-Related Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">RPE65</i>-Related Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chao DL, Burr A, Pennesi M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=22497028" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=22497028" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc94d2dde0891169e1c73c">Bietti Crystalline Dystrophy - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Bietti Crystalline Dystrophy - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:30:58-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE886066DFC85D7100000000074C0345&amp;ncbi_session=CE886066DFC94D11_1868SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK91457%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK91457&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK91457/&amp;ncbi_pagename=Bietti Crystalline Dystrophy - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE886066DFC94D11_1868SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>